APLS
Price
$17.81
Change
-$0.18 (-1.00%)
Updated
May 8 closing price
Capitalization
2.26B
94 days until earnings call
RCKT
Price
$7.04
Change
+$0.73 (+11.57%)
Updated
May 8 closing price
Capitalization
715.46M
94 days until earnings call
Ad is loading...

APLS vs RCKT

Header iconAPLS vs RCKT Comparison
Open Charts APLS vs RCKTBanner chart's image
Apellis Pharmaceuticals
Price$17.81
Change-$0.18 (-1.00%)
Volume$3M
Capitalization2.26B
Rocket Pharmaceuticals
Price$7.04
Change+$0.73 (+11.57%)
Volume$2.68M
Capitalization715.46M
APLS vs RCKT Comparison Chart
Loading...
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APLS vs. RCKT commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLS is a Buy and RCKT is a Hold.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (APLS: $17.81 vs. RCKT: $7.04)
Brand notoriety: APLS and RCKT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APLS: 120% vs. RCKT: 93%
Market capitalization -- APLS: $2.26B vs. RCKT: $715.46M
APLS [@Biotechnology] is valued at $2.26B. RCKT’s [@Biotechnology] market capitalization is $715.46M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APLS’s FA Score shows that 0 FA rating(s) are green whileRCKT’s FA Score has 1 green FA rating(s).

  • APLS’s FA Score: 0 green, 5 red.
  • RCKT’s FA Score: 1 green, 4 red.
According to our system of comparison, RCKT is a better buy in the long-term than APLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APLS’s TA Score shows that 4 TA indicator(s) are bullish while RCKT’s TA Score has 5 bullish TA indicator(s).

  • APLS’s TA Score: 4 bullish, 4 bearish.
  • RCKT’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, RCKT is a better buy in the short-term than APLS.

Price Growth

APLS (@Biotechnology) experienced а -11.30% price change this week, while RCKT (@Biotechnology) price change was -10.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.66%. For the same industry, the average monthly price growth was +15.23%, and the average quarterly price growth was -12.40%.

Reported Earning Dates

APLS is expected to report earnings on Aug 11, 2025.

RCKT is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (-3.66% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
APLS($2.26B) has a higher market cap than RCKT($715M). RCKT (-43.994) and APLS (-44.187) have similar YTD gains . APLS has higher annual earnings (EBITDA): -154.53M vs. RCKT (-247.48M). APLS has more cash in the bank: 411M vs. RCKT (372M). RCKT has less debt than APLS: RCKT (25.5M) vs APLS (470M). APLS has higher revenues than RCKT: APLS (781M) vs RCKT (0).
APLSRCKTAPLS / RCKT
Capitalization2.26B715M316%
EBITDA-154.53M-247.48M62%
Gain YTD-44.187-43.994100%
P/E RatioN/AN/A-
Revenue781M0-
Total Cash411M372M110%
Total Debt470M25.5M1,843%
FUNDAMENTALS RATINGS
APLS vs RCKT: Fundamental Ratings
APLS
RCKT
OUTLOOK RATING
1..100
418
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
28
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9593
PRICE GROWTH RATING
1..100
9064
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCKT's Valuation (28) in the Biotechnology industry is somewhat better than the same rating for APLS (69) in the Medical Distributors industry. This means that RCKT’s stock grew somewhat faster than APLS’s over the last 12 months.

RCKT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as APLS (100) in the Medical Distributors industry. This means that RCKT’s stock grew similarly to APLS’s over the last 12 months.

RCKT's SMR Rating (93) in the Biotechnology industry is in the same range as APLS (95) in the Medical Distributors industry. This means that RCKT’s stock grew similarly to APLS’s over the last 12 months.

RCKT's Price Growth Rating (64) in the Biotechnology industry is in the same range as APLS (90) in the Medical Distributors industry. This means that RCKT’s stock grew similarly to APLS’s over the last 12 months.

RCKT's P/E Growth Rating (100) in the Biotechnology industry is in the same range as APLS (100) in the Medical Distributors industry. This means that RCKT’s stock grew similarly to APLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APLSRCKT
RSI
ODDS (%)
Bullish Trend 1 day ago
67%
Bullish Trend 1 day ago
79%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
80%
Momentum
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
88%
MACD
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
73%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
77%
Advances
ODDS (%)
Bullish Trend 7 days ago
81%
Bullish Trend 7 days ago
80%
Declines
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 3 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
80%
Aroon
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
76%
View a ticker or compare two or three
Ad is loading...
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TLGAX12.43N/A
N/A
Timothy Plan Large/Mid Cap Growth A
USLIX70.68N/A
N/A
JHancock U.S. Global Leaders Growth I
HRTVX44.13N/A
N/A
Heartland Value Investor
OMSIX55.61N/A
N/A
Invesco Main Street R6
MDOBX10.28N/A
N/A
Morgan Stanley Developing Opportunity C